Medartis appoints Dirk Kirsten as Chief Financial Officer and EMB member

Medartis Holding AG / Key word(s): Personnel

11-Dec-2020 / 06:59 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 KR

The issuer is solely responsible for the content of this announcement.


Medartis Holding AG
Hochbergerstrasse 60E
CH-4057 Basel

PRESS RELEASE

Medartis appoints Dirk Kirsten as Chief Financial Officer

Basel, Switzerland, 11 December 2020 – The Board of Directors of Medartis Holding AG (SIX: MED) has appointed Dirk Kirsten as new Chief Financial Officer and Member of the Executive Management Board. He will join Medartis as of 1 march 2021 and will succeed Dominique Leutwyler, who has decided to leave the company.

In his future role as CFO and Member of the Executive Management Board of Medartis, Dirk Kirsten will be responsible for all matters of internal and external group financial management, as well as for the group’s M&A projects, thus actively supporting further growth and envisaged portfolio expansions.

As a proven financial expert with broad industry experience, Dirk Kirsten (1968) has a strong track record in international management, corporate finance and M&A and held various senior management positions in the medtech, pharmaceutical and healthcare sectors. These included the roles as CFO of Nobel Biocare (2008-2013), Group Treasurer of Syngenta (2004-2008) and Head Group Funding & Capital Markets of Roche Holding (2002-2004). Prior to that, he worked with global investment banks, where he specialized in healthcare transactions. In 2013, Dirk Kirsten founded his own advisory boutique focusing on M&A, private equity as well as start-up financing and business development. Dirk Kirsten is a Swiss and German citizen. He holds a PhD in Management & Economics from the University of Cologne and participated in the international MBA program of the London Business School.

Over the last 20 years, Dominique Leutwyler has made a significant contribution as CFO in building the pillars of Medartis on its way from a start-up to a listed company with broad international presence. He established and further developed the group’s finance functions, supply chain and ICT operations and was additionally responsible for the set-up of its production infrastructure and its thirteen subsidiaries as well as for various beneficial M&A activities. He also lead-managed Medartis’ successful IPO in 2018. He will remain in his position until the 2020 full-year results publication on 10 March 2021. The Board of Directors and Executive Management Board regret Dominique Leutwyler’s decision and are grateful to him for his extensive and successful contributions in building Medartis to its current strengths. Medartis wishes him every success for his future.

Contact
Patrick Christ
Head Corporate Services
Medartis Holding AG
Phone: +41 61 633 34 70
patrick.christ@medartis.com

About Medartis
Founded in 1997 and headquartered in Basel, Switzerland, Medartis is one of the world’s leading manufacturers and providers of medical devices for surgical fixation of bone fractures for upper and lower extremities as well as for the craniomaxillofacial region. Medartis employs around 630 individuals across its 13 locations, with products offered in over 50 countries globally. Medartis is committed to providing surgeons and operating theatre personnel with the most innovative titanium implants and instruments as well as best in class service. For more information, please visit www.medartis.com.

Disclaimer
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Medartis Holding AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions. Further, neither the company nor any of its directors, officers, employees, agents, counsel or advisers nor any other person makes any representation or warranty, express or implied, as to, and accordingly no reliance should be placed on, the accuracy or completeness of the information contained herein or of the views given or implied.


End of ad hoc announcement


show this